Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Synairgen SG016
 
NCT04385095
RCTSNG001 inhaled interferon betaplaceboCOVID 19 hospitalizedsome concern
50/51 suggested
  • suggested 1.3-fold increase in clinical improvement with a moderate degree of certainty due to some concern in risk of bias
  • suggested 2.2-fold increase in clinical improvement (28-day) with a moderate degree of certainty due to some concern in risk of bias
1 study excluded by filtering options (1 RCT / 0 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).